Top
Main
 
All Outcomes
 
RCT vs. Obs.
 
Feedback
Home
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — Remdesivir for COVID-19: real-time meta analysis of 79 studies

@CovidAnalysis, November 2024, Version 98V98
Post
Share
PDF
Studies
Feedback
https://c19early.org/smeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Madan (ES) 66% 0.34 [0.12-0.96] death 4/112 27/260 Improvement, RR [CI] Treatment Control PINETREE Gottlieb (DB RCT) 87% 0.13 [0.03-0.59] death/hosp. 2/279 15/283 PINETREE Gottlieb (DB RCT) 72% 0.28 [0.11-0.75] hosp. 5/279 18/283 PINETREE Gottlieb (DB RCT) 29% 0.71 [0.37-1.37] no recov. 43/66 45/60 PINETREE Gottlieb (DB RCT) 48% 0.52 [0.34-0.79] no recov. 108/169 132/165 Killingley -60% 1.60 [0.51-5.03] progression 6 (n) 12 (n) Piccicacco 66% 0.34 [0.01-8.32] death 0/82 1/90 Piccicacco 30% 0.70 [0.28-1.72] hosp. 7/82 11/90 Piccicacco 52% 0.48 [0.21-0.96] hosp./ER 9/82 21/90 Piccicacco 78% 0.22 [0.05-0.97] progression 2/82 10/90 Kneidinger 20% 0.80 [0.35-1.82] severe case 6/46 28/172 Ong -75% 1.75 [0.23-13.0] recov. time 4 (n) 14 (n) Ong -56% 1.56 [0.67-3.60] hosp. time 4 (n) 14 (n) Ong -61% 1.61 [0.86-3.00] viral time 4 (n) 14 (n) Chew -68% 1.68 [0.51-5.58] progression 12 (n) 151 (n) PLATCOV Jittamala (RCT) 66% 0.34 [0.01-8.12] hosp. 0/67 1/69 PLATCOV Jittamala (RCT) 29% 0.71 [0.61-0.83] viral rate 67 (n) 69 (n) Seah -129% 2.29 [0.26-20.1] no recov. 2/7 1/8 Choi -267% 3.67 [0.20-3.27] death 308 (n) 13,656 (n) Choi -600% 7.00 [4.00-11.5] ICU 308 (n) 13,656 (n) Choi -686% 7.86 [6.40-9.40] oxygen 308 (n) 13,656 (n) Choi -182% 2.82 [2.35-3.33] misc. 308 (n) 13,656 (n) Siami -70% 1.70 [0.76-3.82] hosp. 341 (n) 148 (n) Wang (RCT) -9% 1.09 [0.54-2.18] death 22/158 10/78 Wang (RCT) 24% 0.76 [0.29-1.95] death 8/71 7/47 Wang (RCT) -48% 1.48 [0.45-4.88] death 12/84 3/31 Olender 59% 0.41 [0.24-0.71] death 24/312 102/818 Spinner (RCT) 35% 0.65 [0.18-2.40] death 5/384 4/200 Pasquini (ICU) 16% 0.84 [0.69-0.94] death 14/25 24/26 ICU patients Fried 61% 0.39 [0.15-0.99] death 4/48 2,510/11,673 Fried -37% 1.37 [0.81-2.30] ventilation 11/48 1,956/11,673 Beigel (RCT) 27% 0.73 [0.52-1.03] death 541 (n) 521 (n) Beigel (RCT) 45% 0.55 [0.36-0.83] death 541 (n) 521 (n) Beigel (RCT) 22% 0.78 [0.67-0.89] no recov. 541 (n) 521 (n) SOLIDARITY SOLIDARITY .. (RCT) 5% 0.95 [0.81-1.11] death 301/2,743 303/2,708 El-Solh 29% 0.71 [0.52-0.97] death 63/219 202/424 SARSTer Flisiak 49% 0.51 [0.19-1.30] death 5/122 17/211 SARSTer Flisiak 58% 0.42 [0.13-1.18] death 4/82 14/119 SARSTer Flisiak 56% 0.44 [0.21-0.86] no improv. 9/122 36/211 Garibaldi 20% 0.80 [0.46-1.41] death 23/303 45/303 Garibaldi 35% 0.65 [0.53-0.78] no improv. 52/303 80/303 Ullah -100% 2.00 [0.67-5.94] death 8/30 4/30 Ullah -250% 3.50 [0.79-15.5] ventilation 7/30 2/30 Yeramaneni -24% 1.24 [0.11-14.2] death 32 (n) 7,126 (n) Goldberg 9% 0.91 [0.50-1.67] hosp. time 29 (n) 113 (n) Goldberg 0% 1.00 [0.92-1.09] viral+ 29 (n) 113 (n) Tsuzuki -4% 1.04 [0.98-1.09] death 69/824 285/11,663 Tsuzuki 2% 0.98 [0.91-1.07] ventilation 48/824 98/11,663 Tsuzuki 15% 0.85 [0.41-1.77] progression 559/824 1,784/11,663 Mahajan (RCT) -76% 1.76 [0.46-6.82] death 5/34 3/36 Mahajan (RCT) -112% 2.12 [0.41-10.8] ventilation 4/34 2/36 Mulhem -86% 1.86 [0.21-5.24] death 1/8 515/3,211 Haji Aghajani 19% 0.81 [0.46-1.46] death 46 (n) 945 (n) Elhadi (ICU) -11% 1.11 [0.81-1.51] death 14/21 267/444 ICU patients Pourhoseingholi -2% 1.02 [0.72-1.44] death 42/123 297/2,345 Arch (PSM) 20% 0.80 [0.64-0.98] death 203/1,491 777/4,676 Arch (PSM) 18% 0.82 [0.63-1.06] death 140/1,502 565/4,728 Arch (PSM) -68% 1.68 [1.19-2.34] ventilation 106/1,498 153/4,602 Barrat-Due (DB RCT) 0% 1.00 [0.20-4.60] death 3/42 4/57 Barrat-Due (DB RCT) -36% 1.36 [0.29-6.39] death 3/42 3/57 Barrat-Due (DB RCT) 55% 0.45 [0.05-4.20] death 1/42 3/57 Barrat-Due (DB RCT) -47% 1.47 [1.10-1.98] no recov. 42 (n) 76 (n) Barrat-Due (DB RCT) -43% 1.43 [1.09-1.87] no recov. 42 (n) 76 (n) Barrat-Due (DB RCT) -24% 1.24 [0.96-1.60] no recov. 42 (n) 76 (n) Barrat-Due (DB RCT) -50% 1.50 [1.01-2.23] no recov. 42 (n) 76 (n) Ohl (PSM) -6% 1.06 [0.83-1.36] death 143/1,172 124/1,172 Ohl (PSM) -100% 2.00 [1.33-3.02] hosp. time 1,172 (n) 1,172 (n) Madan 44% 0.56 [0.33-0.95] death 23/398 27/260 Madan 66% 0.34 [0.12-0.96] death 4/112 27/260 Madan 62% 0.38 [0.18-0.80] death 9/226 27/260 Madan -60% 1.60 [0.82-3.13] death 10/60 27/260 Madan 31% 0.69 [0.37-1.29] death 19/398 18/260 Madan 35% 0.65 [0.32-1.35] death 14/398 14/260 Madan 48% 0.52 [0.21-1.31] death 8/398 10/260 Madan 35% 0.65 [0.19-2.23] death 5/398 5/260 Madan 13% 0.87 [0.20-3.86] death 4/398 3/260 Kuno (PSM) 1% 0.99 [0.84-1.17] death 214/999 216/999 Kuno (PSM) 0% 1.00 [0.80-1.24] ventilation 140/999 140/999 Kuno (PSM) -17% 1.17 [1.00-1.37] ICU 260/999 222/999 Elavarasi -137% 2.37 [1.98-2.83] death 146/403 207/1,352 Diaz 35% 0.65 [0.46-0.92] death 33/286 173/852 Diaz 44% 0.56 [0.32-0.97] death 286 (n) 852 (n) DISCOVERY Ader (RCT) 6% 0.94 [0.59-1.45] death 34/414 37/418 DISCOVERY Ader (RCT) 12% 0.88 [0.50-1.56] death 21/414 24/418 DISCOVERY Ader (RCT) 10% 0.90 [0.70-1.15] 7-point status 414 (n) 418 (n) DISCOVERY Ader (RCT) -2% 1.02 [0.80-1.30] 7-point status 414 (n) 418 (n) Mozaffari 12% 0.88 [0.81-0.96] death 4,441/28,855 5,499/28,855 Mozaffari 24% 0.76 [0.69-0.83] death 3,057/28,855 4,437/28,855 Schmidt (PSM) -509% 6.09 [2.71-13.7] severe case 43 (n) 434 (n) Jamir (ICU) 8% 0.92 [0.55-1.55] death 60/181 41/85 ICU patients Mustafa 33% 0.67 [0.38-1.20] death 16/200 29/244 CATCO Ali (RCT) 12% 0.88 [0.72-1.07] death 127/634 152/647 CATCO Ali (RCT) 17% 0.83 [0.67-1.03] death 117/634 145/647 CATCO Ali (RCT) 21% 0.79 [0.40-1.58] death 14/634 18/647 CATCO Ali (RCT) 47% 0.53 [0.38-0.75] ventilation 46/634 89/647 CATCO Ali (RCT) 9% 0.91 [0.73-1.14] no recov. 634 (n) 647 (n) CATCO Ali (RCT) -11% 1.11 [1.01-1.23] hosp. time 634 (n) 647 (n) Kurniyanto -460% 5.60 [2.32-13.5] death 7/45 12/432 Siraj 53% 0.47 [0.35-0.62] death 108/413 197/587 Salehi (ICU) 37% 0.63 [0.43-0.94] death 17/40 57/85 ICU patients Elec 19% 0.81 [0.38-1.69] death 7/38 29/127 Elec 11% 0.89 [0.45-1.78] ventilation 8/38 30/127 Elec -72% 1.72 [1.11-2.66] ICU 18/38 35/127 Zangeneh (ICU) 32% 0.68 [0.45-1.01] death n/a n/a ICU patients Malundo -17% 1.17 [0.80-1.70] death 24/115 197/1,100 Bowen -57% 1.57 [1.25-1.97] death 817 (n) 3,814 (n) Raad 42% 0.58 [0.39-0.88] death n/a n/a Oku -40% 1.40 [0.41-4.36] death 3/46 8/172 Behboodikhah 38% 0.62 [0.30-1.30] death 1,214 (n) 960 (n) Cacho -80% 1.80 [0.37-8.82] death 5/57 2/41 Cacho -44% 1.44 [0.53-3.89] severe case 10/57 5/41 Cacho -73% 1.73 [0.93-3.21] m/s case 24/57 10/41 Cacho -92% 1.92 [0.54-6.79] no disch. 8/57 3/41 Hartantri 11% 0.89 [0.31-2.53] death n/a n/a Hartantri 24% 0.76 [0.33-1.77] death n/a n/a Alshamrani (PSM) 17% 0.83 [0.72-0.93] death 137/246 725/1,078 Alshamrani (PSM) 4% 0.96 [0.90-1.00] progression 215/246 984/1,078 Alshamrani (PSM) -43% 1.43 [1.13-1.80] ICU 245 (n) 995 (n) Alshamrani (PSM) 7% 0.93 [0.81-1.05] hosp. time 246 (n) 1,078 (n) Mitsushima -44% 1.44 [1.09-1.90] death n/a n/a Punzalan -42% 1.42 [0.92-2.20] death 47/224 26/176 Punzalan -59% 1.59 [1.19-2.13] progression 93/224 46/176 Kim -1612% 17.12 [0.19-1565] death 14/145 0/22 Aweimer -13% 1.13 [0.93-1.37] death 40/51 68/98 Intubated patients Arfijanto 1% 0.99 [0.64-1.53] viral+ 17/44 46/118 Bavaro (PSW) 7% 0.93 [0.89-0.97] severe case 120 (n) 211 (n) Shamsi -23% 1.23 [0.56-2.69] death 8/53 16/130 Mozaffari (PSM) 25% 0.75 [0.68-0.83] death 14,169 (n) 5,341 (n) Mozaffari (PSM) 30% 0.70 [0.62-0.78] death 14,169 (n) 5,341 (n) Nadeem -12% 1.12 [0.39-3.26] death 12/96 4/36 Burhan (ICU) -15% 1.15 [0.96-1.37] death 33/43 345/516 ICU patients Hagman 0% 1.00 [0.60-1.80] death 105 (n) 213 (n) Hagman 0% 1.00 [0.50-1.90] death 105 (n) 213 (n) Hagman 20% 0.80 [0.30-2.40] death 105 (n) 213 (n) Hagman -40% 1.40 [0.80-2.40] progression 105 (n) 213 (n) Hagman 29% 0.71 [0.50-1.11] viral+ 105 (n) 213 (n) Ho -62% 1.62 [1.35-1.95] death 5,294 (n) 21,151 (n) Amirizadeh (ICU) -3% 1.03 [0.86-1.24] death 31/35 30/35 ICU patients Amirizadeh (ICU) -52% 1.52 [0.83-2.78] ventilation time 35 (n) 35 (n) ICU patients Amirizadeh (ICU) -27% 1.27 [0.86-1.88] ICU 35 (n) 35 (n) ICU patients Amirizadeh (ICU) -24% 1.24 [0.88-1.75] hosp. time 35 (n) 35 (n) ICU patients Muntean -45% 1.45 [1.04-2.03] death 71/287 45/264 Chang -185% 2.85 [1.03-7.85] death 81 (n) 81 (n) Alsaraj (RCT) -83% 1.83 [0.66-5.11] death 9/52 5/53 Liao -25% 1.25 [0.55-2.86] death 37/59 3/6 Sokolski 0% 1.00 [0.67-1.47] death 88 (n) 460 (n) Lewandowski -21% 1.21 [0.66-2.22] death 430 (all patients) Drouin -46% 1.46 [1.15-1.54] severe case 52/102 135/354 Milan -34% 1.34 [0.20-8.91] death 1/8 16/172 Milan -122% 2.22 [0.86-5.78] ventilation 3/8 29/172 Milan -419% 5.19 [3.40-7.92] ICU 7/8 29/172 REDPINE Sise (DB RCT) -0% 1.00 [0.67-1.49] death 51/163 25/80 REDPINE Sise (DB RCT) 17% 0.83 [0.50-1.39] death 41/163 23/80 REDPINE Sise (DB RCT) 18% 0.82 [0.50-1.32] death/int. 48/163 26/80 REDPINE Sise (DB RCT) 16% 0.84 [0.52-1.38] misc. 163 (n) 80 (n) REDPINE Sise (DB RCT) -5% 1.05 [0.64-1.72] misc. 163 (n) 80 (n) Anzalone (PSM) -33% 1.33 [1.29-1.37] death n/a n/a Anzalone (PSM) 8% 0.92 [0.89-0.96] ventilation n/a n/a Kawther -9% 1.09 [0.46-2.57] death 111 (n) 340 (n) Remdesivir COVID-19 outcomes c19early.org November 2024 Favors remdesivir Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0